Morphosys AG - ADR

MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2021 Results - Earnings Call Transcript

MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) reports financial results for the first quarter of 2021. "For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline," said Jean-Paul Kress, M.D.

MorphoSys AG Reports First Quarter 2021 Results

Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT). MorphoSys' Management Board will host a conference call and webcast on May 6, 2021 at 2:00pm CEST (8:00am EDT) to present the first quarter and first 3-month financial results 2021 and provide an outlook for 2021.

DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021

Incyte

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). "Despite improvements in treatment for patients with relapsed or refractory FL and MZL, there continues to be a significant medical need for additional therapies with improved outcomes," said Peter Langmuir, M.D.

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q4 2020 Results - Earnings Call Transcript

PLANEGG, BAVARIA / ACCESSWIRE / March 15, 2021 / Conference call and webcast (in English) tomorrow, March 16, 2021 at 2:00pm CET (1:00pm GMT/9:00am EDT) MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) reports results for the year ended December 31, 2020 and provides a financial and operational outlook for 2021. Financial Highlights for Full Year 2020 The Company achieved revenues of € 327.7 million (2019: € 71.8 million) and EBIT of € 27.4 million (2019: € -107.9 million).

MorphoSys AG Presents Results for Full Year 2020

Conference Call Alert PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 9, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein, and peptide technologies, will publish its results for the financial year 2020 on March 15, 2021 at 10:00 pm CET (5:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 16, 2021 at 2:00 pm CET (9:00 am EDT) to present results for the financial year 2020 and provide an outlook for 2021.

Invitation to MorphoSys' Full Year Results 2020 Conference Call on March 16, 2021

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 2, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmithKline plc (LSE/NYSE: GSK) reported preliminary results of the OSCAR (Otilimab in Severe COVID-19 Related Disease) study using otilimab (formerly MOR103/GSK3196165) for the treatment of severe pulmonary COVID-19 related disease. Given these data suggest an important clinical benefit in a pre-defined sub-group of high-risk patients and the urgent public health need, GSK has amended the OSCAR study to expand this cohort to confirm these potentially significant findings.

MorphoSys's Licensing Partner GSK Shared Preliminary Results From OSCAR Study with Otilimab for the Treatment of Severe Pulmonary COVID-19 Related Disease; Expanding the Study for Patients 70 Years and Older

PLANEGG & MUNICH, GERMANY / ACCESSWIRE / March 01, 2021 / MorphoSys AG preliminary results for the fiscal year 2020 exceeding guidance MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announces that according to the analysis of the preliminary results during the ongoing year-end closing process, MorphoSys' outlook has been exceeded. Group revenues for 2020 are expected to amount to € 327.7 million and therefore slightly above the upper end of the guidance range from € 317 to 327 million.

Morphosys AG Preliminary Results for the Fiscal Year 2020 Exceeding Guidance

Adagene

I-Mab

Eli Lilly

Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement.

Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs

PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 39th Annual J.P.

MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today the appointment of Sung Lee as Chief Financial Officer, effective February 2, 2021. Mr. Lee succeeds Jens Holstein, who stepped down in December 2020, and will lead all corporate finance functions as a member of the Management Board of MorphoSys AG.

MorphoSys Appoints Sung Lee as Chief Financial Officer

Invesco KBW Premium Yield Equity REIT ETF

iShares Preferred and Income Securities ETF 

Vanguard Real Estate ETF

High-Yield equity REITs have regularly underperformed. We expect that trend to continue over the next decadeREITs with high yields, low FFO multiples, and weak balance sheets have regularly underperformed.

6 Reasons To Ditch High Yield REITs

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2021 as follows:   Publication of Interim Statement / Report Conference Call Year-End Results 2020 March 15, 2021 // 10 pm CET (5 pm EDT; 9 pm GMT) March 16, 2021 // 2 pm CET (9 am EDT; 1 pm GMT) First Quarter Interim Statement 2021 May 5, 2021 // 10 pm CEST (4 pm EDT; 9 pm BST) May 6, 2021 // 2 pm CEST (8 am EDT; 1 pm BST) Half-Year Report 2021 July 28, 2021 // 10 pm CEST (4 pm EDT; 9 pm BST) July 29, 2021 // 2 pm CEST (8 am EDT; 1 pm BST) Third Quarter Interim Statement 2021 Nov. 10, 2021 // 10 pm CET (4 pm EST; 9 pm GMT) Nov. 11, 2021 // 2 pm CET (8 am EST; 1 pm GMT)       Annual General Meeting May 19, 2021   For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar With season's greetings and best wishes for the New Year: www.morphosys.com/xmas-2020 About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer.

MorphoSys AG: Corporate Calendar 2021

MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript

Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.

Incyte (INCY), Xencor and MorphoSys Ink Collaboration Deal

Xencor

MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), first-line DLBCL, and relapsed or refractory follicular lymphoma (FL). ‟Xencor is pleased to pa

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST

Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma

Helen of Troy

PennyMac Financial Services

Texas Pacific Land Trust

Profitability analysis is considered one of the best possible ways to assess the prospects of a company.

4 Lucrative Stocks With Amazingly High Net Income Ratio

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

News for Morphosys AG - ADR Stock (MOR)